AOD-9604 is one of the stranger compounds in the peptide universe. It is literally a fragment of human growth hormone — amino acids 177-191 from the GH sequence — that was specifically investigated by its developers because early animal data suggested it mobilized fat without the growth effects of the parent molecule. That selectivity is why it was of pharmaceutical interest. It is also why the subsequent clinical data is so revealing.

The Rationale: Why GH Fragments Were Investigated

Growth hormone has multiple receptor-binding sites and produces multiple effects: fat mobilization (lipolysis), muscle growth (anabolic effects), bone remodeling, immune function regulation, and others. The full GH molecule activates all of these simultaneously, which creates the clinical side effect profile that limits therapeutic use (fluid retention, insulin resistance, potential tumor growth effects).

If you could isolate the fat-mobilizing portion of the GH molecule — specifically the epitope that drives lipolysis without the growth-promoting and metabolic effects — you might have an obesity drug with a better risk-benefit profile than GH itself. That's what AOD-9604 was designed to be.

The amino acid 177-191 fragment was specifically chosen because early studies suggested this region was responsible for the lipolytic activity of GH. A synthetic version of this fragment — AOD-9604 — was developed and entered clinical trials as an anti-obesity drug candidate.

What the Clinical Trials Actually Found

AOD-9604 was developed by a company called Metabolic Pharmaceuticals, which ran Phase I and Phase II clinical trials in the early 2000s. The results were disappointing enough that development was discontinued — a fact that the peptide marketing community has tried very hard to make invisible.

Phase IIa trials in obese patients showed AOD-9604 was well-tolerated but produced no statistically significant weight loss compared to placebo at any dose tested. Phase IIb trials — larger, better-controlled — confirmed this result: no meaningful weight loss. The lipolytic effects that made sense in animal models did not translate to clinically meaningful fat loss in humans at the doses and route used in the trials.

The development of AOD-9604 as an obesity drug was terminated. This is public record. Metabolic Pharmaceuticals' pipeline was wound down, and AOD-9604 became one of the more prominent examples of a peptide compound that was abandoned by its own developers because the human data didn't support the indication.

Then it got picked up by the peptide gray market. The "burns fat without diet or exercise" claim for AOD-9604 got a 9/10 — the most skeptical score of any peptide claim we've evaluated. Not because the lipolysis mechanism is impossible, but because the only controlled human trial data we have showed it doesn't work at the doses used clinically.

The "Big Pharma Buried It" Conspiracy Theory

The conspiracy theory that Big Pharma buried AOD-9604 because it threatens Ozempic is one of the more inventive pieces of peptide marketing. It requires believing that:

  • A compound that failed Phase II clinical trials for the exact indication being claimed (weight loss) is actually a suppressed blockbuster.
  • The entire pharmaceutical industry, multiple regulatory agencies, and peer-reviewed journals have successfully suppressed or mischaracterized the positive data.
  • Peptide clinics, compounding pharmacies, and gray-market suppliers have independently discovered this suppressed wonder drug and are selling it legitimately despite having no FDA approval or clinical trial support.

The actual explanation — that the compound was tested, didn't work at the doses studied, and development was discontinued by its own developers — is simpler and consistent with the evidence. The conspiracy theory requires extraordinary assumptions about coordination and suppression that are implausible on their face.

What AOD-9604 Actually Is Today

AOD-9604 is available as a "research chemical" through compounding pharmacies and gray-market peptide suppliers. It is not FDA-approved for any indication. It has no regulatory approval status in any major market. The quality control issues that apply to all unregulated peptides apply here: batch-to-batch variability, potential contamination, incorrect concentration, no accountability for adverse events.

Clinics that prescribe AOD-9604 are running a treatment protocol based on a compound that failed its own clinical trials for the exact condition being treated. That is a significant epistemic problem. The mechanism may be real; the clinical translation is what's missing — and that absence is not explained by a pharmaceutical conspiracy.

The IGF-1 Issue (It's Not Neutral)

Some versions of AOD-9604 marketing claim the compound has "no growth effects, no IGF-1 elevation, no side effects." The "no growth effects" claim is what the early research was trying to establish — and it's the claim that makes the compound interesting. But the "no side effects" claim is a category mistake: a compound with "no growth effects" is not the same as "no biological effects." AOD-9604 binds to the same GH receptor (or closely related receptors) that mediate the lipolytic signal. It is not inert. Its full pharmacological profile, including potential long-term effects on metabolism, glucose regulation, and other GH-dependent systems, has not been characterized in humans.

Bottom Line

AOD-9604 has an interesting story: a GH fragment that was rationally designed to separate fat mobilization from growth effects, entered clinical trials for obesity, and failed those trials at the doses and routes tested. The failure was published and the development was discontinued by the company that owned it. This is not a suppressed wonder drug. It's a compound that was tested in humans and didn't produce the expected outcome at clinically relevant doses.

The peptide gray market selling it is selling a compound with Phase II clinical trial data against it, sold at compounding pharmacy markups with no quality control accountability and no regulatory approval. The "burns fat without diet or exercise" framing is the most dishonest claim in the peptide space — not because the mechanism is impossible, but because we have controlled human data specifically addressing this claim, and it says no.

Before spending money on AOD-9604, look at what Metabolic Pharmaceuticals found when they actually ran the trial. The data is public. It says the claim is wrong.